[No public or meaningful name is available]

Basic toxicokinetics

Administrative data

Endpoint:

basic toxicokinetics

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

other:

Data source

Reference

Reference Type:

other company data

Title:

Unnamed

Year:

2011

Report date:

2011

Materials and methods

Test material

Test material information

Constituent 1

Reference substance name:

700-380-4

EC Number:

700-380-4

Molecular formula:

A: C25H50O2 B: C27H54O2

IUPAC Name:

700-380-4

Details on test material:

- Name of test material: SymMollient S
- Molecular formula: A: C25H50O2; B: C27H54O2
- Molecular weight: A: 382.68 g/mol; B: 410.73 g/mol
- Flashpoint: 198.5 °C
- Self ignition temperature: 320 °C
- Melting point: 22 °C
- Boiling point: 412 - 417 °C
- Physical state: solid to liquid
No further information on the test material was stated.

Applicant's summary and conclusion

Conclusions:

statement on ADME please refert to "executive summary"

Executive summary:

Inhalation absorption

The potential for dust inhalation is considered to be of no relevance, since the substance at room temperature (20-25°C) is a liquid to waxy solid and not a powder with an inhalable size.Taking into account the vapour pressure of 3*10^-5Pa at 25°C of SymMollient®S and the low water solubility(A: 3.5 µg/L/ B: 1.7 µg/L) inhalation of vapours can also be completely ruled out.

 

Oral absorption

SymMollient® S is of low water soluble (A: 3.5 µg/L/ B: 1.7 µg/L) and highly lipophilic (log Pow (calculated) = 11.2 / 12.2), therefore absorption may be limited by the lowability to dissolve in GI fluids and hence to be available in soluble form at the mucosal surface. However, the absorption will be enhanced if they undergo micellular solubilisation by bile salts.

Dermal absorption

see IUCLID endpoint 7.1.2 "dermal absorption"

Distribution

The substance is expected to reach the systemic circulation only to a very limited extend and in addition it is expected to be readily metabolised after passing the liver. Therefore, distribution SymMollient® S throughout the body is not very likely.

Metabolism and elimination

The carboxylesterase hydrolyses the carboxylic esters into a carboxylate and alcohol.

The alcohol will be oxidised in the liver to an aldehyde, catalysed by the alcohol/dehydrogenase containing the coenzyme NAD⁺. The aldehyde is further oxidised to the respective carboxylate. Both carboxylates will be broken down into acetyl-CoA-units, which will be metabolised in the citrate cycle just like the conventional metabolism of natural fatty acids, ultimately yielding carbon dioxide as respiration product.

In consequence, if small amounts of SymMollient® S reach the systemic circulation, the substance may be expected to be readily biotransformed to harmless, endogenous cellular constituents of the energy-producing metabolic pathway.

 

The alcohol will be oxidised in the liver to an aldehyde, catalysed by the alcohol/dehydrogenase containing the coenzyme NAD⁺. The aldehyde is further oxidised to the respective carboxylate. Both carboxylates wil be broken down into acetyl-CoA-units, which will be metabolised in the citrate cycle just like the conventional metabolism of natural fatty acids, ultimately yielding carbon dioxide as respiration product.